- Home
- ATOS vs PROF Comparison
ATOS vs PROF Comparison
Compare ATOS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PROF
- Stock Information
- Founded
- ATOS 2009
- PROF N/A
- Country
- ATOS United States
- PROF Canada
- Employees
- ATOS N/A
- PROF N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- ATOS Health Care
- PROF Health Care
- Exchange
- ATOS Nasdaq
- PROF Nasdaq
- Market Cap
- ATOS 130.5M
- PROF 130.4M
- IPO Year
- ATOS 2012
- PROF N/A
- Fundamental
- Price
- ATOS $0.98
- PROF $5.90
- Analyst Decision
- ATOS Strong Buy
- PROF Strong Buy
- Analyst Count
- ATOS 3
- PROF 1
- Target Price
- ATOS $6.25
- PROF $11.00
- AVG Volume (30 Days)
- ATOS 1.3M
- PROF 172.4K
- Earning Date
- ATOS 11-11-2025
- PROF 11-13-2025
- Dividend Yield
- ATOS N/A
- PROF N/A
- EPS Growth
- ATOS N/A
- PROF N/A
- EPS
- ATOS N/A
- PROF N/A
- Revenue
- ATOS N/A
- PROF $11,840,000.00
- Revenue This Year
- ATOS N/A
- PROF $60.07
- Revenue Next Year
- ATOS N/A
- PROF $121.80
- P/E Ratio
- ATOS N/A
- PROF N/A
- Revenue Growth
- ATOS N/A
- PROF 59.81
- 52 Week Low
- ATOS $0.55
- PROF $3.76
- 52 Week High
- ATOS $1.66
- PROF $9.17
- Technical
- Relative Strength Index (RSI)
- ATOS 57.15
- PROF 59.95
- Support Level
- ATOS $0.86
- PROF $5.72
- Resistance Level
- ATOS $1.29
- PROF $7.17
- Average True Range (ATR)
- ATOS 0.08
- PROF 0.43
- MACD
- ATOS 0.01
- PROF 0.09
- Stochastic Oscillator
- ATOS 38.23
- PROF 47.35
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.